Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.

Abstract

OBJECTIVES:

The aim of this study is to assess the cost-effectiveness of fruquintinib compared to regorafenib as third-line treatment for patients with metastatic colorectal cancer (mCRC) in China.

METHODS:

A three-state Markov model with monthly cycle was constructed to estimate lifetime incremental cost-effectiveness ratio (ICER) of fruquintinib versus regorafenib as third-line treatment for patients with mCRC from Chinese health care perspective. Survival analysis was applied to calculate transition probabilities using the data from the clinical trials FRESCO and CONCUR, which were also the data sources accessing probabilities of adverse events. Background mortality rate and drug costs were derived from government published data. Costs for medical services were obtained from real-world data and published literatures. Utilities applied to calculate the quality-adjusted life years (QALYs) were obtained from literature review. One-way sensitivity analysis and probabilistic sensitivity analysis were adopted to verify the robustness of the results.

RESULTS:

Fruquintinib provided 0.74 QALYs at a cost of CNY 151,058 (USD 22,888), whereas regorafenib provided 0.79 QALYs at a cost of CNY 226,657 (USD 32,224). Compared to fruquintinib, the ICER of regorafenib was CNY 1,529,197/QALY (USD 231,697/QALY) from Chinese health care perspective, which was above the triple GDP per capita of China in 2019 (CNY 212,676) (USD 32,224) as the threshold to define the cost-effectiveness. One-way sensitivity analysis showed the results were generally robust. Cost-effectiveness acceptability curves derived from probabilistic sensitivity analysis demonstrated the probability that fruquintinib was more cost-effective was 100% when the threshold was the triple GDP per capita of China.

CONCLUSIONS:

Compared to regorafenib, fruquintinib, which leads to forego about 0.05 QALYs and save about CNY 75,599 (USD 11,454), is a cost-effective choice as the third-line treatment for patients with mCRC in China.

• Authors: Xin Guan, Hongchao Li, Xiaomo Xiong, Cike Peng, Ning Wang, Xiao Ma, Aixia Ma
• Journal: Journal of medical economics (J Med Econ) 2021 Jan-Dec Vol. 24 Issue 1 Pg. 339-344 ISSN: 1941-837X [Electronic] England
• PMID: 33571036 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Benzofurans
• Phenylurea Compounds
• Pyridines
• Quinazolines
• regorafenib
• HMPL-013

Topics

• Antineoplastic Agents (adverse effects, economics, therapeutic use)
• Benzofurans (adverse effects, economics, therapeutic use)
• China
• Colorectal Neoplasms (drug therapy, pathology)
• Cost-Benefit Analysis
• Health Expenditures (statistics & numerical data)
• Health Resources (economics, statistics & numerical data)
• Humans
• Markov Chains
• Models, Economic
• Neoplasm Metastasis
• Phenylurea Compounds (adverse effects, economics, therapeutic use)
• Pyridines (adverse effects, economics, therapeutic use)
• Quality-Adjusted Life Years
• Quinazolines (adverse effects, economics, therapeutic use)